ISS’ endorsement comes as other hedge funds have spoken out against the deal. The merger, which would create a healthcare giant with 22 million members, also faces tough regulatory and antitrust scrutiny.
Mr. Japsen writes ISS’ recommendation is usually a positive sign for mergers. According to ISS, cited by Forbes, “[Centene] did not conduct an auction, and the merger consideration is below the company’s all-time high closing price. However, the merger appears sound strategically and financially, and the merger consideration implies meaningful premia to the company’s historical valuation and its unaffected price. As such, support for the transaction is warranted.”
Centene and WellCare announced their deal in March.
More articles on payer issues:
4 updates on payer-provider relations
Group Health Cooperative partners with Fort HealthCare
Henry Ford Health insurer’s CEO Terri Kline on decision to buy a Medicaid plan
